Class Action Lawsuit Filed Against Neumora Therapeutics, Inc.:
New York, NY – March 7, 2025 – Levi & Korsinsky, LLP announces that a class action securities lawsuit has been commenced in the United States District Court for the Southern District of New York on behalf of investors who purchased Neumora Therapeutics, Inc. (“Neumora Therapeutics” or the “Company”) (NASDAQ: NMRA) securities between February 11, 2021, and February 28, 2025. The lawsuit seeks to recover damages for Neumora Therapeutics investors under the Securities Exchange Act of 1934.
Class Definition:
The class action lawsuit seeks to recover losses on behalf of Neumora Therapeutics investors who were adversely affected by alleged securities fraud. The complaint alleges that the Company issued materially false and misleading statements and failed to disclose material information to the investing public.
Background:
Neumora Therapeutics is a clinical-stage biopharmaceutical company focused on the development of cannabinoid therapeutics for the treatment of pain and inflammation. The Company’s lead product candidate, NM-001, is a cannabinoid receptor type 2 agonist being developed for the treatment of chronic pain.
Allegations:
The complaint alleges that Neumora Therapeutics made false and misleading statements and failed to disclose material information to investors. Specifically, the Company is accused of overstating the prospects of NM-001, failing to disclose the risks associated with the development of NM-001, and making false and misleading statements regarding the Company’s financial condition and prospects.
Impact on Individual Investors:
If you purchased Neumora Therapeutics securities between February 11, 2021, and February 28, 2025, you may be entitled to recover your losses. Investors who wish to learn more about the lawsuit and their potential eligibility for recovery should contact Levi & Korsinsky, LLP by emailing [email protected] or visiting https://www.zlk.com/consultation-request/?id=1168-nmra-class-action-lawsuit-nmra-stock.
Impact on the World:
The class action lawsuit against Neumora Therapeutics could have significant implications for the biopharmaceutical industry, particularly for companies developing cannabinoid therapeutics. The lawsuit highlights the importance of transparency and accuracy in disclosing information to investors, particularly regarding the risks and prospects of clinical-stage drug candidates.
Conclusion:
The filing of a class action securities lawsuit against Neumora Therapeutics is a significant development for investors who purchased the Company’s securities between February 11, 2021, and February 28, 2025. The lawsuit alleges that Neumora Therapeutics made false and misleading statements and failed to disclose material information to investors. If you purchased Neumora Therapeutics securities during this period, you may be entitled to recover your losses. For more information, please contact Levi & Korsinsky, LLP.
About Levi & Korsinsky, LLP:
Levi & Korsinsky, LLP is a national firm with offices in New York, New Jersey, Connecticut, and California. The firm’s attorneys have extensive expertise in prosecuting securities litigation involving financial fraud, accounting fraud, and consumer protection violations. For more information, please visit https://www.zlk.com.
- Contact: Levi & Korsinsky, LLP
- Email: [email protected]
- Phone: 212-363-7500
- Website: https://www.zlk.com
